Arcadia Biosciences, Inc. (Nasdaq: RKDA) issued a press release on November 12, 2026, detailing its financial results for the third quarter of 2026. The company reported that total revenues for the quarter increased by $317,000, or 24%, compared to the same period in 2025, reaching $1.619 million. This growth was driven by strong volumes from summer programs, resulting in the highest quarterly sales in the brand's history.
Net income attributable to common stockholders for the third quarter of 2026 was $1.755 million, or $0.29 per share. This represents a $900,000 improvement compared to the $856,000 net income, or $0.63 per share, reported for the third quarter of 2025. The increase in net income was primarily driven by a $2.6 million gain related to the change in the estimated fair value of common stock warrant and option liabilities.
Regarding product developments, the company announced that it began shipping its newly formulated espresso flavor this month. The Zola Espresso product is available in a 1-liter resealable carton and contains just over 100 milligrams of caffeine. Additionally, the company stated that its Zola Original, Original with Pulp, and Espresso varieties will be available in a 10.5-ounce slim can in the first half of 2027.
The company also provided a financial snapshot for the first nine months of 2026. Total revenues for the nine-month period increased by $205,000, or 5%, to $4.162 million. However, the company reported a net loss attributable to common stockholders of $8.896 million, or $2.39 per share, compared to a net loss of $1.003 million, or $0.73 per share, for the same period in 2025.
